Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM‐406/AT‐406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer by Zhang, Tao et al.
BIOPHARMACEUTICS & DRUG DISPOSITION
Biopharm. Drug Dispos. 34: 348–359 (2013)
Published online 01 August 2013 in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/bdd.1850Physiologically based pharmacokinetic and pharmacodynamic
modeling of an antagonist (SM-406/AT-406) of multiple
inhibitor of apoptosis proteins (IAPs) in a mouse xenograft
model of human breast cancer
Tao Zhanga,†, Yanyan Lia,‡, Peng Zoua, Jing-yu Yua, Donna McEachernb, Shaomeng Wangb, and Duxin Suna,*
aDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, 48109, USA
bComprehensive Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann
Arbor, MI, 48109, USACorresp
Univer
-mail:
Curren
esearch
J, 0793
Curren
ciences
CopyrigABSTRACT: The inhibitors of apoptosis proteins (IAPs) are a class of key apoptosis regulators
overexpressed or dysregulated in cancer. SM-406/AT-406 is a potent and selective small molecule
mimetic of Smac that antagonizes the inhibitor of apoptosis proteins (IAPs). A physiologically based
pharmacokinetic and pharmacodynamic (PBPK-PD) model was developed to predict the tissue concen-
tration–time proﬁles of SM-406, the related onco-protein levels in tumor, and the tumor growth inhibi-
tion in a mouse model bearing human breast cancer xenograft. In the whole body physiologically
based pharmacokinetic (PBPK) model for pharmacokinetics characterization, a well stirred (perfusion
rate-limited) model was used to describe SM-406 pharmacokinetics in the lung, heart, kidney, intestine,
liver and spleen, and a diffusion rate-limited (permeability limited) model was used for tumor. Pharma-
codynamic (PD) models were developed to correlate the SM-406 concentration in tumor to the cIAP1
degradation, pro-caspase 8 decrease, CL-PARP accumulation and tumor growth inhibition. The
PBPK-PD model well described the experimental pharmacokinetic data, the pharmacodynamic bio-
marker responses and tumor growth. This model may be helpful to predict tumor and plasma
SM-406 concentrations in the clinic. Copyright © 2013 John Wiley & Sons, Ltd.
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Apoptosis (programmed cell death) is a critical
cellular process to maintain normal development
and homeostasis of multicellular organisms.
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One of the key features that distinguish cancer
cells from normal cells is apoptosis avoidance
and resistance, which has been a major hurdle to
current therapies [4]. Therefore, targeting crucial
apoptosis regulators to overcome the evasion of
cancer cell death has emerged as a promising ther-
apeutic strategy.
A class of key apoptosis regulators has been iden-
tiﬁed, which are named as the inhibitors of apopto-
sis proteins (IAPs), including X-linked IAP (XIAP),
cellular IAP1 and IAP2 (cIAP1 and cIAP2) [5–7].
XIAP is a central regulator of both death receptor
mediated and mitochondria mediated apoptosisReceived 17 December 2012
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349PBPK/PD MODELING OF AN ANTAGONIST OF IAPSpathways, inhibiting apoptosis by directly binding
to caspase-3, caspase-7 and caspase-9 [7]. The cIAP1
and cIAP2 play a crucial role in regulating tumor
necrosis factor receptor – associated factor (TRAF)
mediated apoptosis and suppressing caspase-8 acti-
vation [5–7]. Second mitochondria derived acti-
vator of caspases (Smac) protein, also known as
DIABLO (direct inhibitor of apoptosis-binding
protein with low pI), has been identiﬁed as an
endogenous antagonist of IAP proteins [8,9]. It has
been proposed that SMAC interacts with XIAP
and cIAP1/2 proteins via its Ala-Val-Pro-Ile (AVPI)
tetrapeptide binding motif to promote the activa-
tion of caspases and to induce apoptosis [10–13].
SM-406/AT-406 is a small molecule mimetic of
Smac currently being evaluated in clinical phase I
studies as an anticancer agent [14]. It was designed
based upon the crystal structure of Smac and
conﬁrmed to be a selective and potent antagonist
of the IAP proteins [14]. SM-406 bound to XIAP,
cIAP1 and cIAP2 with Ki of 66.4, 1.9 and 5.1 nM
[14]. In a cell-free functional assay, SM-406 com-
pletely antagonized XIAP and restored the activity
of caspase-9 at 1μM [14]. In human breast cancer
cells, it rapidly and effectively induced cIAP1 deg-
radation at 100nM [14]. SM-406 exhibited moderate
bioavailability after oral administration in the mice,
rat, dog and non-human primates [14].
In the drug discovery and development
process, pharmacokinetic-pharmacodynamic (PK-
PD) modeling has been applied increasingly, partic-
ularly for selecting drug candidates with favorable
PK-PD properties and optimizing study design. It
is not only a valuable tool to understand the phar-
macokinetic property and therapeutic response of
an existing compound, but can also provide
important information for evaluating new chemical
entities. Generally the PK-PD relationship is estab-
lished with preclinical data to obtain an insight of
the drug action mechanism in vivo. The commonly
used methodologies for PK prediction are allome-
tric scaling and physiologically based pharmaco-
kinetic (PBPK) modeling. PBPK models are
mathematical models derived from the anatomical
and physiological structure of the organism studied
[15]. PBPKmodels are considered to be mechanisti-
cally based, because they reﬂect our knowledge of
the mechanisms of the underlying pharmacokinetic
process. Although the establishment of PBPK
models can be tedious and requires extensive effortCopyright © 2013 John Wiley & Sons, Ltd.of both physiological and drug speciﬁc parameters
input and mathematical analysis, it offers the major
advantage of greater extrapolation power [15].
Pharmacodynamic studies can provide information
on the mechanism or dose–response relationship of
a drug, and the response can be classiﬁed as
biomarkers, surrogate end points or clinical end
points [16]. By building a PK-PD model, the kinetic
information can be related to the observed effect
and provide a better understanding of the drug
exposure and sequence of the events resulting in
the drug effect [16].
The objective of the present study was to investi-
gate the PK-PD relationship of SM-406 inmice bear-
ing human breast cancer xenografts. A PBPKmodel
was developed to describe the concentration–time
proﬁles of SM-406 in the tissues, and a PD model
was established to characterize the biomarker
response in tumor and tumor growth kinetics.
Finally, an integrated PBPK-PD model was gener-
ated to give a full pharmacokinetic and efﬁcacy pro-
ﬁle of SM-406 in vivo.Materials and Methods
Chemicals
SM-406 and an internal standard (IS) SM-408 for
LC-MS/MS were synthesized as described previ-
ously [14]. Acetonitrile and methanol of HPLC-
grade were purchased from Fisher Scientiﬁc
(Pittsburgh, PA,USA).Distilledwaterwas produced
in house by a Milli-Q water puriﬁcation system
(Millipore Corp., Bedford, MA). Ammonium acetate
(HPLC-grade) and formic acid (spectroscopic grade)
were purchased from Sigma/Aldrich (MO, USA).
In vivo pharmacokinetics studies
The mouse model bearing human MDA-MB-231
xenograft tumor was employed in this study. To
develop xenograft tumors, 5 × 106 MDA-MB-231
cancer cells were mixed with matrigel and injected
subcutaneously on the dorsal side of severe
combined immunodeﬁcient SCID mice (Charles
River Laboratories, Wilmington, MA). SM-406 was
dissolved in PBS and the pH was adjusted with
NaOH as needed. The pH of the drug solutions
was checked before administration to ensure it
was between pH3.0 and 9.0 for oral administrationBiopharm. Drug Dispos. 34: 348–359 (2013)
DOI: 10.1002/bdd
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istration. Mice bearing MDA-MB-231 xenograft
tumors were administered with control vehicle or
a single intravenous dose of SM-406 at 10mg/kg,
single oral doses of SM-406 at 30 and 100mg/kg
delivered by oral gavage. There were three mice
per time point. Blood samples were collected into
heparinized tubes from each mouse by terminal
cardiac puncture at 0.25, 0.5, 1, 2, 4, 6, 8, 24 h
postdose. The plasma fraction was immediately
separated by centrifugation at 4 °C and stored at
80 °C until analysis. For the 100mg/kg group,
liver, lung, heart, kidney, tumor, spleen and intes-
tine were also immediately dissected, weighed,
snap-frozen and ground with a mortar and pestle
in liquid nitrogen, and then stored at 80 °C until
analysis. An additional two groups of mice (3 or 4
per group) were dosed and placed in metabolic
cages (Harvard Apparatus, South Natick, MA) for
separate collection of urine and feces. All animal
experiments were performed under the guidelines
of the University of Michigan Committee for Use
and Care of Animals.
The quantitative determination of the plasma, tis-
sue, urine and feces concentration of SM-406 was
donewith LC-MS/MS using an Agilent 1200HPLC
system coupled to an API 3200 mass spectrometer
(Applied Biosystems, MDS Sciex Toronto, Canada)
equipped with an API electrospray ionization
(ESI) source as described previously [14]. The mass
spectrometerwas operated at ESI positive ionmode
and the detection of the ions was performed in the
multiple reaction monitoring (MRM) mode,
monitoring the transition of m/z 562.3 precursor
ion [M+H]+ to the m/z 167.1 product ion for SM-
406 and m/z 610.2 precursor ion [M+H]+ to the
m/z 167.1 product ion for internal standard (SM-
408). Mobile phase A and B were water and metha-
nol, and both contained 5mM ammonium acetate
and 0.1% formic acid (v/v). The ﬂow gradient
was initially 90:10 v/v of A:B for 2min, linearly
ramped to 0:100 over 4min, held at 0:100 for
2min, and then returned to 90:10 over 0.1min. This
condition was held for a further 5min prior to the
injection of another sample. The ion spray voltage
was set at 5500V. The ionization temperature was
set as 700 °C. The instrument parameters, curtain
gas, gas 1 and gas 2 (auxillary gas), were set at 20,
60 and 60, respectively. The compounds parame-
ters, declustering potential (DP), collision energyCopyright © 2013 John Wiley & Sons, Ltd.(CE), entrance potential (EP), collision entrance
energy (CEP) and collision exit potential (CXP)
were 61, 45, 5, 26, 4V and 61, 45, 9, 27.3, 4V for
SM-406 and IS (SM-408), respectively. Data acquisi-
tion and quantitationwere performed using analyst
software version 1.4.2 (Applied Biosystems, MDS
Sciex Toronto, Canada).
Plasma samples were prepared by mixing
plasma with acetonitrile containing IS. The solution
was vortexed for 1min at high speed and centri-
fuged at 13000 rpm for 10min to precipitate protein.
The clear supernatant was transferred to vial inserts
for LC-MS/MS analysis. Calibration standard
solutions were prepared with blank plasma. The
lower limit of quantiﬁcation was 1ng/ml. Intra-
day variability was assessed through analysis of
QCs in triplicate and the inter-day variability was
determined by analysing QCs on three different
days, and the CV%was less than 5%. To prepare tis-
sue samples, about 60–80mg of ground tissue pow-
der was weighed and mixed with PBS to obtain
ﬁnal concentrations (w/v) of 200mg/ml. Samples
were homogenized using a tissue homogenizer
(Tissuemiser Homogenizer, Fisher Scientiﬁc) for
20 s. Then the homogenate was treated similarly
as for plasma for LC-MS/MS analysis. Calibration
standard solutions were preparedwith blank tissue
homogenate. The lower limit of quantiﬁcation for
tissue samples ranged from 2.5 to 12.5 ng/g. Urine
samples were processed similarly to plasma, and
feces were homogenized ﬁrst before subjecting to
a similar procedure.In vivo pharmacodynamic studies
Mice bearing MDA-MB-231 xenografts tumors
were orally administered with a single dose of
100mg/kg SM-406, and tumor tissues were
harvested at 2 h, 6 h, 16 h and 24 h. The tumor tis-
sues for mice administered with control vehicle
were collected at 24 h. Tumor tissues were lysed
using radioimmunoprecipitation assay (RIPA)
lysis buffer (PBS containing 1% NP-40, 0.5%
sodium deoxycholate and 0.1% sodium dodecyl
sulfate [SDS]) supplemented with 1μM pheny-
lmethylsulfonyl ﬂuoride and one protease inhibi-
tor cocktail tablet per 10ml on ice for 20min,
and lysates were then cleared by centrifugation
prior to protein concentration determination
using BCA assay kit (Pierce, Rockford, IL)Biopharm. Drug Dispos. 34: 348–359 (2013)
DOI: 10.1002/bdd
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Proteins were electrophoresed onto 18% SDS-
PAGE gels (Invitrogen, Grand Island, NY) and
transferred to PVDF membranes. Following
blocking in 5% milk, the membranes were incu-
bated with a speciﬁc primary antibody, washed
and incubated with horseradish peroxidase linked
secondary antibody (Amersham, Piscataway, NJ).
The signals were visualized with the chemilumi-
nescent HRP antibody detection reagent
(Denville Scientiﬁc, Metuchen, NJ). When indi-
cated, the blots were stripped and reprobed with
a different antibody. The following primary anti-
bodies were used in the study: anti-cIAP (from
R&D), anti-procaspase-8 (Stressgen Biotechnol-
ogies, Victoria, Canada) and anti-PARP (Cell
Signaling Technology, Beverly, MA). Quantiﬁca-
tion of western blotting bands was performed
by densitometry analysis with Image J software
(NIH, Bethesda, MD).
To determine the antitumor activity of SM-406,
SCID mice bearing MDA-MD-231 xenograft
tumors were orally administered vehicle, 30mg/kg
and 100mg/kg of SM-406 daily (5days per week)
for 2weeks. The tumor length and width were mea-
sured using a digital caliper 2–3 times a week and
tumor volumes were calculated using the formula,
volume (mm3)=L×W2/2 (length L, mm; width W,
mm) as described previously [17].Blood distribution and protein binding
Plasma protein binding was measured as de-
scribed previously [18]. Plasma was spiked with
SM-406 to yield a ﬁnal concentration of 1μg/ml
and 5μg/ml. After incubation at 37 °C for 1 h, an
aliquot was transferred to a 10 kD cut-off ultraﬁl-
tration device (Millipore Corporation, Billerica,
MA, USA), and was centrifuged at 1500 × g for
1 h at 37 °C. The samples were analysed by LC-
MS/MS as described above. The concentrations
of SM-406 in the ﬁltrate were determined by a
standard curve constructed with known concen-
trations of SM-406 in protein-free plasma (macro-
molecules had been removed from the plasma by
10 kD cut-off ultraﬁltration). The unbound frac-
tion was estimated from the ratio of SM-406 con-
centration in the ﬁltrate to that in the original
plasma samples. Compound dissolved in pro-
tein-free plasma was studied in parallel to showCopyright © 2013 John Wiley & Sons, Ltd.that SM-406 binds minimally to the ultraﬁltration
device. The calculated unbound fraction in
plasma (fup) at 1μg/ml is 0.185 and at 5μg/ml is
0.195, and the average of 0.19 was used in further
studies.
To determine blood to plasma partitioning
(Kb/p), SM-406 (1 and 5μg/ml) was added to
mice blood (2ml) and incubated at 37 °C for 1 h
with very gentle shaking. After incubation, ali-
quots of blood (50μl) were removed, and the
remaining blood was centrifuged at 1000 × g for
10min to separate plasma. The concentrations
of SM-406 in whole blood and plasma were de-
termined using LC-MS/MS and separate calibra-
tion curves were constructed with blank blood
and plasma spiked with known concentrations
of SM-406. The blood to plasma ratio (Kb/p) is
determined by the drug concentration in blood
compared with plasma. The blood to plasma ra-
tio (Kb/p) at 1μg/ml is 1.02 and at 5μg/ml is
1.06, so an average of 1.04 was used. The con-
centration of SM-406 in venous blood was calcu-
lated from: Cven(t) =Cp(t)*Kb/p, where Cp is the
plasma concentration.
Physiologically based pharmacokinetic model
Local models were built with blood and tissue
concentration–time data after the oral administra-
tion of 100mg/kg SM-406. The plasma drug con-
centration–time curve declines in biexponential
manner, so in local models, a commonly used
two-compartment model with extravascular ad-
ministration was employed to describe the plasma
concentration–time data. The plasma model used
ﬁrst order absorption and elimination. Both
perfusion rate-limited and diffusion rate-limited
models were evaluated for each tissue and the
selection of ﬁnal models was based on the quality
of ﬁts and the Akaike information criteria.
The mass-balance differential equations for well
stirred organs (lung, heart, spleen, intestine, kidney,
muscle) were listed below:
VTissue•
dCTissue
dt
¼ QTissue• Cart 
CTissue
RTissue
 
The mass-balance differential equations for diffu-
sion-limited organs (tumor, rest of the body) were:Biopharm. Drug Dispos. 34: 348–359 (2013)
DOI: 10.1002/bdd
Table 1. Physiological parameters used in the whole body
PBPK model for tumor-bearing mice
Total volume
(ml)
Vascular
volume
(as % of
organ volume)
Organ blood
ﬂow
(% cardiac
output)
Whole body 19.74a – –
Blood 1.003b – 100
Lung 0.155a – 100
Liver 1.147a – 16.1b
Spleen 0.034a – 0.42d
Intestine 1.113a – 11.99d
Heart 0.114a – 6.6b
Kidney 0.324a – 9.1b
Tumor 0.475a 10c 1.73c
Muscle 7.860b – 15.9b
Rest of body 8.245a 10c 50.57
aDetermined by averaging the experimental data for each organ and
assuming a density of 1 g/ml except for bone, 1.5 g/ml; average body
weight (BW)= 20.47 g.
bValues obtained from Brown et al. [21].
cValues obtained from Baxter et al. [20].
dValues obtained from Wang et al. [19], cardiac output = 51.36ml/min/
100 g BW.
352 T. ZHANG ET AL.VTissue v•
dCTissue v
dt
¼ QTissue• Cart  CTissue vð Þ  PSTissue
•fub• CTissue v  CTissue evRTissue
 
VTissue ev•
dCTissue ev
dt
¼ PSTissue•fub• CTissue v  CTissue evRTissue
 
Where QTissue represents organ blood ﬂow rate,
VTissue represents organ volume, VTissue_v repre-
sents the volume of vascular space, VTissue_ev rep-
resents the volume of extravascular space, Cart
represents the input from arterial blood, fub repre-
sents the free fraction in blood. For lung organ, the
input is the output from blood: QLung*Cven, PSTissue
represents permeability surface area product, and
RTissue represents the partitioning coefﬁcient.
The mass-balance differential equations for
eliminating organs liver and kidney were listed
below:
Vli•
dCli
dt
¼ Qsp•
Csp
Rsp
þQin•
Cin
Rin
þ Qhp-Qsp-Qin
 
•Cart-Qhp•
Cli
Rli
- f ub•CLintli
Cli
Rli
Vki•
dCki
dt
¼ Qki•Cart-Qki•
Cki
Rki
- CLr•Cki
Where Qsp, Qin, Qhp, Qki represent the spleen,
intestine, hepatic and kidney blood ﬂow rate, Vli
and Vki represent liver and kidney volume, Csp,
Cin, Cli, Cki and Cart represent drug concentrations
in each organ, CLint_li represents the intrinsic clear-
ance with respect to free drug concentration in the
liver, and CLr represents renal clearance.
The physiologic parameters were either obtained
from the literature or determined by experiment
and listed in Table 1 [19–21]. The initial estimates
of the partitioning coefﬁcient were determined by
the ratio of the area under concentration curves
(AUC) between tissue and blood. The AUC values
were calculated using noncompartmental analysis
with WinNonlin software (Pharsight Corporation,
Cary, NC, USA). In nonsampled muscle tissue the
value was estimated with the PBPKPlus™ module
of Gastroplus software, which incorporated the
physiochemical property such as logP, pKa andCopyright © 2013 John Wiley & Sons, Ltd.plasma protein binding of the compound
(Simulations Plus Inc., Lancaster, USA). The param-
eters obtained from individualmodels were used as
initial estimates for the whole body model. The
whole body PBPKmodel depicts the body as being
composed of nine tissue compartments and one
blood compartment (Figure 1). Oral administration
was treated as a bolus into a dummy depot
compartment from which a fraction of the dose
(F%) could enter the blood with the ﬁrst-order rate
constant. All equations were solved simultaneously
with the maximum likelihood estimator in the
ADAPT 5 software [22]. The variance model was
deﬁned as: VARi = (σinter +σslope ·Yi(tj))2, where
VARi is the variance of the ith data point, σinter,
σslope are the variance model parameters. The esti-
mated values for σinter and σslope are 0.10 and 0.53.
The bioavailability was obtained by comparing
the plasma AUC of oral dose (100mg/kg) with
the intravenous dose (10mg/kg).
Pharmacodynamic model
To characterize the relationship between the SM-
406 concentration and efﬁcacy, an integrated
PBPK-PD model (Figure 2) was established using
the PBPK estimated tumor SM-406 concentration
as an input to modulate onco-protein levels andBiopharm. Drug Dispos. 34: 348–359 (2013)
DOI: 10.1002/bdd
Figure 1. Whole body PBPK model for SM-406 following an
oral dose. Subscripts are: ven, venous blood; lu, lung; ht, heart;
tu, tumor; li, liver; sp, spleen; in, intestine; ki, kidney; mu, mus-
cle; rb, rest of the body
Figure 2. Schematic illustration of the caspase activation and
apoptosis pathway model linking tumor SM-406 concentration
(CSM-406 ) to onco-protein levels and tumor growth inhibition.
cIAP, cellular inhibitors of apoptosis proteins; CL-PARP,
cleaved PARP; Sti, stimulation; Inh, inhibition
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Copyright © 2013 John Wiley & Sons, Ltd.tumor growth inhibition. The PD model was built
based on the molecular mechanism of caspase
activation and apoptosis pathways with some
modiﬁcations [23,24]. The inhibition/stimulation
of onco-protein degradation or tumor apoptosis
was described by the following equations:
dcIAPI
dt
¼ Rsyn cIAP1
Kdeg cIAP1•cIAPI• 1þ Emax cIAP1•CtumorEC50 cIAP1 þ Ctumor
 
Where Rsyn_cIAP1 is the zero order formation of
cIAP1, Kdeg_cIAP1 is the ﬁrst order rate constant
deﬁning the degradation of cIAP1, Emax_cIAP1 is the
maximum stimulatory effect of SM-406 on cIAP1
degradation, EC50_cIAP1 is the concentration produc-
ing 50% stimulatory effect. The level of cIAP1 at
baseline is set at 1, so Rsyn_cIAP1 =Kdeg_cIAP1.
dpCAS8
dt
¼ Rsyn pCAS8
Kdeg pCAS8•pCAS8• 1 KpCAS8• cIAPI-1ð Þ
 
Where Rsyn_pCAS8 is the zero order formation of
pCAS8, Kdeg_pCAS8 is the ﬁrst order rate constant
deﬁning the degradation of pCAS8, KpCAS8 is the
constant describing the effect of cIAP1 on pCAS8
degradation. The baseline level of pCAS8 is set
at 1, so Rsyn_pCAS8 =Kdeg_pCAS8.
CL PARP ¼ InterCL PARP  SlopeCL PARP•pCAS8
Where the CL_PARP and pCAS8 levels are
described by a linear relationship based on the data.
The baseline level of CL_PARP is set at 1, so
InterCL_PARP=SlopeCL_PARP+1.
The tumor growth model was built on a simple
exponential growth modiﬁed with a logistic
function containing a maximum tumor volume
(TVmax) [25].
dTV
dt
¼ Rtu grow•TV• 1 TVTVmax
 
 TV•CL PARP•Ktu apop
Where TV is tumor volume, Rtu_grow and Ktu_grow
correspond to tumor growth and apoptosis rate,
TVmax is the maximum tumor volume. When
tumor is very small, the ratio of TV/TVmax is closeBiopharm. Drug Dispos. 34: 348–359 (2013)
DOI: 10.1002/bdd
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order rate; when tumor reaches maximum size,
the ratio of TV/TVmax approximates 1 and there is
no more net growth. The initial estimates for
tumor growth parameters were generated with
WinNonlin (Pharsight Corp., Mountain View, CA)
software using tumor size data from control,
30mg/kg and 100mg/kg treatments simulta-
neously and the whole PBPK-PD model was built
with the ADAPT 5 software [22].Results
PBPK model
The plasma and tissue concentration–time proﬁles
of observed data after 100mg/kg dose of SM-406
were shown in Figure 3 (solid circles). The whole
body PBPK model for SM-406 in MDA-MD-231
xenograft tumor bearing SCID mice is depicted
in Figure 1. The physiological parameters for the
whole body PBPK model were either obtained
from the literature or determined by experiment
and are listed in Table 1. The blood to plasma ratio
(Kb/p) was 1.04 and the unbound fraction in
plasma (fup) was 0.19. All equations were solvedFigure 3. Plasma and tissue concentration–time proﬁles of SM-406 fo
circles represent observed concentrations (mean± SD, n=3) and th
Copyright © 2013 John Wiley & Sons, Ltd.simultaneously with the maximum likelihood
estimator in the ADAPT 5 software [22] and the
ﬁtted concentration–time proﬁles are shown in
Figure 3 (solid lines). It appears from the graphs
that the model captured the plasma concentra-
tion–time proﬁles quite well. After oral adminis-
tration, the estimated ﬁrst-order absorption rate
constant was 0.974 h-1.
Concentration–time proﬁles for lung, heart,
kidney, intestine, liver and spleen captured by
the PBPK model are also depicted in Figure 3
(solid lines). Concentration–time curves of these
organs declined approximately in parallel with
that of blood, so the well stirred model was used.
The model depicted the observed data relatively
well for most organs. The tissue-to-blood partition
coefﬁcient (RT) calculated by noncompartmental
analysis and those estimated from the PBPK
model are reported in Table 2. Model-deﬁned RT
values were obtained with good precision with
CV% less than 20%. The deviation between the
noncompartmental and PBPK-deﬁned RT values
never exceeded 1.5-fold. The model obtained liver
intrinsic clearance was 685ml/h, which corres-
ponded to a systemic liver clearance of 40.8ml/h.
The renal clearance of 7.6ml/h was calculated
based on the total amount of drug recoveredllowing an oral dose (100mg/kg) in tumor-bearing mice. Solid
e lines are model-ﬁtted proﬁles
Biopharm. Drug Dispos. 34: 348–359 (2013)
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Table 2. Physiological pharmacokinetic parameters for SM-406 using the whole body PBPK model
Parameter Estimated value CV% Partition coefﬁcient (R) by AUC ratioc
fu,plasma 0.19
a – –
F% (bioavailability) 42.7%a – –
Ka (1/h) 0.974 6.52 –
Rlung 6.0 12.4 7.73
Rheart 1.86 12.4 2.57
Rtumor 2.24 7.19 3.17
Rkidney 6.4 12.4 8.43
Rspleen 3.31 12.5 4.65
Rintestine 7.5 13.9 –
Rliver 10.69 16.9 11.25
Rmuscle 1.15
b – –
Rrest of body 11.75 7.67 –
CLrenal (ml/h) 7.60
a – –
CLint liver 685.3 15.08 –
PStumor (ml/h) 5.63 14.47 –
PSrest of body 106 18.67 –
aFixed values, determined from experimental data.
bNot estimated.
cValues estimated from non-compartmental analysis.
355PBPK/PD MODELING OF AN ANTAGONIST OF IAPSunchanged in the urine. The unchanged SM-406
recovered from feces was negligible.
The tumor concentration–time data were
described with a diffusion/permeability-limited
model (Figure 3). The model divided the organ
into a vascular and extravascular space and
captured the data very well. The model yielded
an estimate of 5.63ml/h for the permeability
surface area product. The rest of the body
compartment for lumped nonsampled tissues was
also characterized with the diffusion-limited model
based upon the hypothesis that the heterogeneity of
the tissues comprising the compartment was
responsible for the polyexponential behavior.Figure 4. Plasma and tumor concentration–time proﬁles of SM-406
circles represent observed concentrations (mean± SD, n=3) and th
Copyright © 2013 John Wiley & Sons, Ltd.PBPK model validation
The established PBPK model from 100mg/kg
dose was used to predict the plasma and tumor
concentration–time proﬁle after administration of
30mg/kg SM-406 to tumor bearing mice, and
the simulated proﬁles were compared with the
observed data (Figure 4). Overall, the model pre-
dicted concentration–time proﬁle agreed well with
the observed data.
PBPK-PD model
Smac (second mitochondria-derived activator of
caspases) has been identiﬁed as an endogenousfollowing an oral dose (30mg/kg) in tumor-bearing mice. Solid
e lines are PBPK model-simulated proﬁles
Biopharm. Drug Dispos. 34: 348–359 (2013)
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Table 3. Pharmacodynamic parameter estimates for
onco-protein and tumor model
Parameter Unit Estimated value CV%
Onco-protein model
Rsyn_cIAP norm.conc./h 0.45 71.4
Emax_cIAP – 3.1 38.9
EC50_cIAP μM 12.0 48.1
Rsyn_pCAS8 norm.conc./h 46.2 85.1
KpCAS8 – 2.68 30.7
SlopeCL_PARP – 35.9 20.0
Tumor growth inhibition model
Rtu_growth 1/h 0.0068 1.00
Ktu_apop 1/h 0.00067 1.80
Tumax mm
3 1260 0.60
356 T. ZHANG ET AL.antagonist of XIAP and cIAPs [8,9]. Smac binds to
cIAPs to induce their degradation, whose absence
activates caspase-8, caspase 3, promotes PARP
cleavage and induces cell apoptosis [23,24]. To
characterize the effect of SM-406 on cIAP1 inhibi-
tion and tumor apoptosis, we built a PBPK-PD
model based on the molecular mechanism of
apoptosis induction signaling pathways. The
schematic illustration of the model is shown in
Figure 2. The PBPK estimated tumor SM-406 was
used directly to modulate cIAP1 degradation,
which further regulated pro-caspase 8, cleaved
PARP (CL-PARP).
The ﬁtted results of onco-protein level using in-
direct response model are shown in Figure 5. The
base levels of cIAP1, pro-caspase 8 and CL-PARP
were set at 1. The simple Emax model was applied
to describe the stimulation of cIAP1 degradation
by SM-406 concentration in tumor. The effect of
cIAP1 on pro-caspase 8 was characterized with a
linearmodel. The accumulation of CL-PARP proﬁle
had a negative correlation with the pro-caspase
proﬁle so a linear relationship was employed. The
model ﬁtted cIAP1 and pro-caspase 8 peak levels
showed up between the 2h and 6h time point.
The model caught the trend of the protein level
change and described the sparse data reasonably
well (Figure 5). The pharmacodynamic parameters
generated from the model were listed in Table 3.
The synthesis rate constants for the proteins were
expressed as normalized amount over time.
In vivo tumor growth in xenograft models is
known to be exponential at least in the early phases
of tumor development, followed by a linear growthFigure 5. Observed and model-ﬁtted onco-protein levels in tumor-b
circles represent measurements and the lines are model-ﬁtted proﬁ
Copyright © 2013 John Wiley & Sons, Ltd.and a ﬁnal plateau, as described by a Gompertz
model [26–28]. Based on our data, we assumed a
maximum tumor volume (TVmax), at which tumor
could not grow any more. When the tumor size
approached TVmax, tumor size increased very
slowly [25]. The tumor growth proﬁles of control,
30mg/kg and 100mg/kg group were ﬁtted simul-
taneously with the above mentioned indirect
responsemodel usingCL-PARP level as amediator.
Both observed data and model predictions are
shown in Figure 6. The estimated parameters were
listed in Table 4. The model adequately represented
the observed data and the parameters were esti-
mated with good precision. The control tumor grew
approximately linearly before reaching a plateau.
The 2-week treatment with 30mg/kg or 100mg/kg
SM-406 effectively delayed the tumor growth, and
the delay was well described by the model. After
that, the tumor grew in a similar manner to that ofearing mice following an oral dose of 100mg/kg SM-406. Solid
les
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Figure 6. Observed and model-ﬁtted tumor growth proﬁles in
control and treated mice bearing tumors. The mice were dosed
daily (5 days/week) with 30mg/kg/day or 100mg/kg/day
SM-406 for 2weeks. Symbols represent measurements (mean±
SD, n= 3) and the lines are model-ﬁtted proﬁles. Arrows indi-
cate the treatment period
357PBPK/PD MODELING OF AN ANTAGONIST OF IAPSthe control as shown in the ﬁgure. The model
estimated the tumor growth and apoptosis rate con-
stant of 6.8 × 10-3 and 6.7× 10-4 h-1, respectively. The
estimatedmaximum tumor volume was 1260mm3,
which was a reasonable estimate for mice xeno-
grafts because of the nutrient limitation. Besides,
mice with a tumor over 1000mm3 need to be eutha-
nized according to the guidelines of the University
of Michigan Committee for Use and Care of
Animals.Discussion
Apoptosis is a critical process in cancer
development and progression [4]. One of the most
promising targeted therapeutic strategies for cancer
therapy is to inhibit the uncontrolled proliferation
and induce apoptosis in cancer cells [4]. Apoptosis
can be activated through intrinsic and extrinsic
pathways, both ending with the activation of
caspases to generate the morphology typical of
apoptosis [29]. The IAPs negatively regulate the
activity of mature caspases and Smac is the endog-
enous antagonist of IAPs [29]. It has been shown
that Smac expression is reduced in tumor progres-
sion inmany cancer types and probably contributes
to intrinsic resistance to chemo- or radiotherapy
[29]. SM-406, a potent small molecule mimetic ofCopyright © 2013 John Wiley & Sons, Ltd.Smac synthesized recently, is currently being
evaluated in phase I clinical trial for human cancer
treatment [14].
The present study characterized the concentration–
time proﬁles for SM-406 in blood, tumor and typical
major organs after oral administration to mice bear-
ing human xenografts, and established a PBPK-PD
model to correlate SM-406 tumor concentration
with Smac mediated intrinsic apoptosis pathway
and tumor growth inhibition.
The development of PBPKmodels for pharmaco-
kinetic characterization offers many advantages. It
helps to gain insight of the pharmacokinetic behav-
ior of the compound in different organs. The results
of the present study showed that SM-406 distrib-
uted extensively to various organs. The compound
was quickly absorbed and distributed after oral
administration. In lung, blood, kidney and liver, it
reached Cmax at 15min. For all the other tested
organs, the Tmax was no more than 1h. Because
the concentration–time proﬁles in most organs
appeared to be in parallel with the blood proﬁle,
the well stirred model was able to describe the data
well (Figure 3). For tumor, both perfusion- and
diffusion-limited model were evaluated, and the
diffusion-limited model can better depict the
concentration–time data. This seems reasonable
because the human xenograft tumor was inocu-
lated subcutaneously, the distribution of the com-
pound into tumor may be hindered by different
barriers. Some deviation occurred in the prediction
of spleen concentration during the elimination
phase (Figure 3).We assumed that the drug reached
equilibrium instantaneously throughout the entire
organ from the incoming plasma ﬂow, so the pre-
dicted proﬁle in spleen showed a similar trend
compared with plasma. However, the observed
data appeared to show that SM-406 was cleared
much faster from spleen than from plasma. One
explanation for this phenomenon is the unknown
clearance mechanism in the spleen, which seems
unlikely to our knowledge. Another reason is that
spleen was the smallest organ tested in the study,
which only had an averageweight of 34mg. During
sample processing we could only weigh a smaller
amount and add ~10 folds solution (v/w) for
homogenization, which might introduce a larger
error in concentration determination.
The absorption rate constant estimated by PBPK
model was 0.974 1/h, which is very close to theBiopharm. Drug Dispos. 34: 348–359 (2013)
DOI: 10.1002/bdd
358 T. ZHANG ET AL.value generated by compartmental analysis. The
tissue-to-blood partition coefﬁcients (R) estimated
by PBPK were within 1.5-fold difference compared
with the AUC ratio from a noncompartmental
analysis, indicating a good ﬁt. In the PBPK model,
both renal clearance and metabolic biotransforma-
tion in the liver were included as the elimination
routes. Renal clearance contributed slightly to the
total clearance since only about 15% of unchanged
parent compound was recovered compared with
the total amount absorbed. The liver intrinsic clear-
ance estimated by PBPK model was 685ml/h,
corresponding to a system clearance of 40.8ml/h.
The system clearance estimated from compartmen-
tal analysis was 53.9ml/h, and the calculated renal
clearance was 7.7ml/h based on the unchanged
compound secreted in urine. The clearance values
from PBPK model and compartmental analysis
were quite consistent. Compared with the hepatic
blood ﬂow of 102ml/h in mice [19], SM-406
showed a moderate clearance with an average half
life of around 3h. The developed PBPK model
was able to simulate the plasma and tumor concen-
tration–time proﬁles in the xenograft mice orally
administered with a lower dose of 30mg/kg
(Figure 4). A slight overestimation was observed,
suggesting possible saturation of the elimination
process since 100mg/kg was quite a high dose.
The molecular mechanisms of the intrinsic apo-
ptosis pathway have been studied extensively
[29], and the selective targeting of IAPs by SM-406
has been demonstrated at the sub-cellular and
molecular level [14]. As a Smac mimetic, SM-406
directly bound to IAPs to prevent their interaction
with caspases and resulted in IAPs degradation
[14]. Thus, caspases 8, 3 and 9 were activated
accordingly, promoting PARP cleavage and induc-
ing apoptosis [14]. To investigate the pharmacoki-
netic and biomarker relationship, a combined
PBPK-PD model was established by linking the
tumor concentration–time proﬁles with onco-
protein levels. This concept was previously intro-
duced in the model of an Hsp90 inhibitor 17-AAG
in xenograft mice, and the model provided insight-
ful conclusions on the kinetic and dynamic charac-
teristics of the compound [30]. However, due to
the extensive data and analysis required, this kind
of model was seldom applied in other compounds.
In our model, we not only included the onco-
protein levels, but also connected it with the ﬁnalCopyright © 2013 John Wiley & Sons, Ltd.efﬁcacy of tumor growth inhibition. In the indirect
response model, the synthesis of the onco-proteins
was assumed to be zero-order and degradation
was by ﬁrst order. The model adequately described
the cIAP1, pro-caspase 8 and CL-PARP protein
levels after the single dose administration of SM-
406 (Figure 5). Upon activation, PARPwere cleaved
and the cleaved PARP accumulated while cIAP1
level decreased. Although no other caspases data
were available, it was very likely after activation
theywould show a similar trend to CL-PARP based
on the knowledge of the underlying mechanisms
[23,24]. The in vivo tumor growth has been known
to follow three stages, exponential growth, linear
growth and plateau, which can be described with
a Gompertz model [27]. A mathematical model
describing this growth behavior has been proposed
and tested extensively on a few compounds [28]. In
the present study, the tumor growthwasmonitored
after reaching 100mm3, so a simpliﬁed growth
model containing a logistic function was employed
[25]. Themodel described the tumor growth in both
control and treatment group reasonably well and
estimated the growth and apoptosis rate constants
of 6.8 × 10-3 and 6.7 × 10-4 h-1,which were close to
the estimates previously reported [31,32].
In conclusion, an integrated PBPK-PDmodelwas
developed to describe the plasma and tissue distri-
bution, onco-protein change and tumor growth
inhibition of a small molecule mimetic SM-406 after
oral administration in a human xenograft mice
model. The PBPK-PD model well described the
experimental pharmacokinetic data, the pharmaco-
dynamics biomarker responses and tumor growth.
This model may be helpful to predict tumor and
plasma SM-406 concentrations in the clinic.Conﬂict of Interest
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